Advertisement
Table 2 Patient’s characteristics
| Variables | Patients without VAP (n = 135) | Patients with VAP (n = 55) | P |
|---|---|---|---|
| Male gender, n (%) | 87 (64.4) | 41 (74.5) | 0.23 |
| Age (year), median (IQR) | 59.2 (52.2–65.8) | 60.4 (50.2–67.1) | 0.99 |
| Cancer type | 0.39 | ||
| Haematological malignancy, n (%) | 95 (70.4) | 35 (63.6) | |
| Solid tumour, n (%) | 40 (29.6) | 20 (36.4) | |
| Cancer stage | 0.91 | ||
| Diagnosis, n (%) | 36 (26.7) | 15 (27.3) | |
| Complete remission, n (%) | 29 (21.5) | 13 (23.6) | |
| Partial remission, n (%) | 31 (23) | 14 (25.5) | |
| Evolutive, n (%) | 39 (28.9) | 13 (23.6) | |
| HSCT, n (%) | 47 (24.7) | 14 (25.4) | 0.43 |
| Admission purpose | 0.32 | ||
| Septic shock, n (%) | 59 (43.7) | 21 (38.2) | |
| Acute respiratory failure, n (%) | 51 (37.8) | 27 (49.1) | |
| Coma, n (%) | 14 (10.4) | 2 (3.6) | |
| Others, n (%) | 11 (8.1) | 5 (9.1) | |
| Clinical sepsis upon admission | 0.042 | ||
| Respiratory, n (%) | 79 (58.5) | 31 (56.4) | |
| Non-respiratory, n (%) | 31 (23) | 6 (10.9) | |
| None, n (%) | 25 (18.5) | 18 (32.7) | |
| Characteristics upon admission | |||
| Neutropenia, n (%) | 54 (40) | 18 (32.7) | 0.41 |
| Antibiotherapy, n (%) | 104 (77) | 43 (78.2) | 1 |
| Corticosteroids (curative), n (%) | 32 (23.7) | 19 (34.5) | 0.15 |
| SOFA score (day of intubation), median (IQR) | 11 (8–14) | 11 (8–13) | 0.28 |
| Characteristics at the first 48 h of MV | |||
| Vasopressors, n (%) | 99 (73.3) | 44 (80) | 0.36 |
| Renal replacement therapy, n (%) | 28 (20.7) | 9 (16.4) | 0.55 |
| Substitutive hydrocortisone, n (%) | 96 (71.1) | 26 (47.3) | 0.003 |
| G-CSF, n (%) | 20 (14.8) | 9 (16.4) | 0.82 |
| Enteral nutrition, n (%) | 40 (29.6) | 21 (38.2) | 0.3 |
| Antibiotherapy | 0.09 | ||
| Adapted, n (%) | 41 (30.4) | 11 (20) | |
| Empirical, n (%) | 89 (65.9) | 38 (69) | |
| None, n (%) | 5 (3.7) | 6 (10.7) |
